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ABSTRACT
Objective: To analyze potential intravenous drug interactions, and their level of severity 
associated with the administration of these drugs based on the prescriptions of an 
intensive care unit. Method: Quantitative study, with a retrospective exploratory design, 
and descriptive statistical analysis of the ICU prescriptions of a teaching hospital from 
March to June 2014. Results: The sample consisted of 319 prescriptions and subsamples 
of 50 prescriptions. The mean number of drugs per patient was 9.3 records, and a higher 
probability of drug interaction inherent to polypharmacy was evidenced. The study 
identified severe drug interactions, such as concomitant administration of Tramadol with 
selective serotonin reuptake inhibitor drugs (e.g., Metoclopramide and Fluconazole), 
increasing the risk of seizures due to their epileptogenic actions, as well as the simultaneous 
use of Ranitidine-Fentanyl®, which can lead to respiratory depression. Conclusion: 
A previous mapping of prescriptions enables the characterization of the drug therapy, 
contributing to prevent potential drug interactions and their clinical consequences.
DESCRIPTORS
Drug Interactions; Patient Safety; Intensive Care Units; Critical Care Nursing; 
Infusions,  Intravenous.
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INTRODUCTION
Drug interaction (DI) is characterized by a change in 
the action of a drug, caused by concomitant or previous 
administration of other medication(s). When drugs have 
a synergistic effect, the therapeutic effect may be potenti-
ated; when antagonistic, concurrent administration may 
reduce their efficacy. In addition, drug interaction can 
interfere in the way drugs are absorbed, metabolized and/
or eliminated(1).
The term “Theoretical Potential Drug Interactions” 
(TPDI) refers to the interactions already registered in the 
literature among the drugs present in the medical prescrip-
tion, which may have occurred or not(2).
Some drug interactions may be intentional; this interaction 
is treated as beneficial or desired. They may also be part of the 
patient’s drug therapy, such as the concomitant administra-
tion of fentanyl and midazolam. This interaction is indicated 
to provide comfort and relief from anxiety in patients under 
mechanical ventilatory support, optimizing synchronization 
and oxygenation(3). However, even a desired drug interaction 
requires observation and monitoring of clinical effects.
To date, there is no consensus in the literature regard-
ing the correct terminology for drug interaction because, in 
addition to the term “adverse event”, some authors treat DI 
as a medication error in the phase of medication prescription, 
or as a failure in monitoring a drug therapy(4).
The main risk factors that contribute to the occurrence 
of these unwanted drug interactions are classified into: 
patient-related, drug-related, and prescription-related fac-
tors. Risk factors associated with patients are: age, concomi-
tant pathology, and polypharmacy; with drugs, potential 
enzyme inhibitors or inducers, therapeutic margin and dose; 
and finally, the medical prescription-related factors, which 
refer to the high number of prescribed drugs, associated 
with the complexity of the clinical condition and intra- and 
extra-hospital prescriptions(4).
The complexity of this care can be observed in the inten-
sive care unit (ICU), where the treatment of hospitalized 
patients usually requires the prescription of multiple medi-
cations, which directly increases the probability of one or 
more drug interactions(2). The results of the Harvard Medical 
Practice Study II indicate a 44.3% to 95% occurrence of 
potential drug interactions(5). Thus, it is important to high-
light the relevance of studying potential drug interactions 
in the ICU.
It is worth noting that the risk of drug-drug interac-
tion increases with the number of drugs prescribed, in 
which the frequency of drug interaction may exceed 80% 
in prescriptions presenting polypharmacy(6). Therefore, it is 
important to know this field well to characterize the most 
commonly used drug therapy, and thus to know the most 
likely interactions.
In the drug therapy system, prescription is crucial for 
patient safety, and deserves extreme attention in the prepara-
tion, so that the chance of error is the smallest possible. A 
study by the American Medical Association revealed that 
56% of medication errors occur in the prescription phase(7). 
Therefore, prescription is the first barrier in order to hinder 
the occurrence of drug interaction.
Medical status, complexity, and polypharmacy are very 
important elements involving DI. In addition, the drug’s 
route of administration is paramount because it can deter-
mine the speed and severity of the drug interaction(2). In this 
study, we approached the drugs administered intravenously; 
it is noted that, because administration is made directly into 
the circulation, very rapid adverse responses can often occur.
Based on the above, the following research questions were 
created: Which are the most important drug classes? What 
are the potential drug interactions and degrees of severity?
Aiming to contribute to the knowledge about potential 
drug interactions in the ICU and, as a consequence, also con-
tribute to the nursing and multidisciplinary team practice, 
the objective of the present study was to analyze potential 
drug interactions, and the respective degrees of severity of 
intravenous medications from the medical prescriptions in 
an intensive care unit.
METHOD
This is a quantitative approach study, using the explor-
atory retrospective design, mediated by documentary analy-
sis of the drug prescriptions of the intensive care unit of a 
teaching hospital in Rio de Janeiro. This is a public reference 
hospital, part of the Sentinel Network, considered a center of 
excellence in teaching, research and extension. The ICU of 
this hospital is divided into surgical and clinical areas, each 
with six beds, and the former has greater patient turnover.
Data collection took place between July and August 
2014, in the medical records of patients hospitalized from 
June 2013 to June 2014. For sample calculations, the number 
of patients admitted in this period was surveyed, being a 
population of 485 admissions. Considering a sample error 
of 5% and a 95% confidence interval, the calculated sample 
was 110 records. For prescription stratification, the days of 
patient hospitalization in the period were counted; total-
ing 7,920 prescriptions. With a sample error of 5% and 
95% confidence interval being calculated, a sample of 319 
prescriptions was obtained.
Inclusion criteria were: prescriptions of patients hospital-
ized from June 2013 to June 2014; prescriptions with the 
physician register number, and drugs administered intrave-
nously. Exclusion criteria were: illegible handwritten pre-
scriptions, and medical records with no ICU prescriptions. 
The selection of medical records to obtain prescriptions was 
randomized from the list of patients hospitalized in the facil-
ity, with one out of five patients being chosen.
Prescriptions were then selected from these and, in each 
medical record, at least one, and at most five prescriptions 
were analyzed. To do so, the authors established the maxi-
mum number of prescriptions to ensure the presence of at 
least one different drug in each prescription, thus avoiding 
repeated drug mapping.
Data extracted from the prescriptions were: gender, age, 
drug name, and intravenous drug pharmaceutical form. The 
database was built using the software Excel® 2007, and the 
data were submitted to a descriptive statistical analysis. In 
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order to answer the research questions, the sample of 110 
medical records and 319 prescriptions was considered for 
the drug characterization and subsequent grouping accord-
ing to drug class.
Of the total number of medical records, 50 were ran-
domly extracted in order to better refine the treatment 
of TPDIs, based on the Micromedex® Healthcare Series 
system, a support tool containing reliable databases, with 
information based on systematic reviews of drugs, toxicol-
ogy and other previous mapping of prescriptions, which 
provides the characterization of drug therapy of notorious 
worldwide knowledge(8).
The limitations of the research were due to the fact that 
some prescriptions were incompletely filled in because they 
were related to unstable patients, who often require the addi-
tion of medications. It is also considered that drug schedul-
ing must be analyzed in future studies.
The present study is part of the integrated research proj-
ect entitled: Boas Práticas Aplicadas à Segurança do Paciente: 
estudo sobre administração medicamentosa (Good Practices 
Applied to Patient Safety: a study on drug administration), 
approved by the institution’s Research Ethics Committees 
under Report no. 336.436, of August 1, 2013/CAAE 
17589513.0.0000.5238. Because this is a study with human 
beings, it is in compliance with Resolution No. 466/2012 of 
the National Health Council.
RESULTS
 The sample represents approximately 23% of the popula-
tion that went through the ICU during the research period. 
It is a heterogeneous group, with several reasons for ICU 
admission, such as acute and postoperative cases of high 
complexity, with patients aged between 20 and 86 years. A 
total of 140 drugs with different dosages, 33 drug classes, 
and a mean of 9.3 drugs per prescription were prescribed, 
with a standard deviation of ± 5.3.
 The drugs found in the prescriptions were grouped into 
33 drug classes, and the classes with the greatest relevance at 
the ICU were: electrolyte replacement (25.19%), antibiotics 
(10.61%), anti-peptic ulcer (10.09%), antipyretics (8.41%) 
and antiemetics (8.37%), as illustrated in Figure 1, which 
shows the percentage of drugs per drug class.
 In the 50 medical records, with one prescription each, 
the number of drugs per patient and their singularities could 
be observed. Figure 2 shows the number of drugs per patient, 
with a maximum of 23, and a minimum of 1 drug.
 Chart 1 shows the number of prescriptions per drug, 
which were divided into 3 groups (A, B and C) according to 
the frequency in prescriptions. Group C is the most promi-
nent, because it consists of drugs prescribed more than ten 
times. The most frequent drugs in this group were: Dipyrone 
(44 prescriptions), Saline Solution 0.9% (36 prescriptions), 
Ringer Lactate (24 prescriptions), Omeprazole (23 prescrip-
tions) and Bromopride (20 prescriptions).
 The search for theoretical potential drug interactions 
in the prescriptions was made based on the Micromedex® 
system, using the Drug Interactions tool, which shows the 
incompatibility of each drug. In addition, this tool classifies 
interactions as to their degree of severity into: contraindicated, 
when concomitant use is not indicated; severe, when it presents 
a risk of death and/or requires an intervention to minimize 
serious adverse effects; moderate, when the DI may result in an 
exacerbation of the patient’s clinical condition; or mild, when 
DI has a limited clinical effect(8). The following illustration 
shows several potential drug interactions among the drugs of 
group B, group C and between groups B and C (Figure 3).
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Figure 1 – Number of drugs per drug class sorted by frequency – Teaching Hospital, Rio de Janeiro, Rio de Janeiro, Brazil, 2014.  
Source: Created by the research authors.
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Figure 2 – Number of drugs per patient – Teaching Hospital, Rio de Janeiro, Rio de Janeiro, Brazil, 2014. 
Source: Created by the research authors.
Chart 1 – Number of prescriptions per drug – Teaching Hospital, Rio de Janeiro, Rio de Janeiro, Brazil, 2014.
DRUg no. OF PRESCRIPTIOnS DIVISIOn In gROUPS ACCORDIng TO THE FREQUEnCY OF PRESCRIPTIOnS
FREQUEnCY OF 
PRESCRIPTIOnS
Cefepime 0
gROUP A < 5 PRESCRIPTIOnS
Sodium nitroprusside 0
Azithromycin 0
nitroglycerine 0
Tenoxicam 0
Heparin 0
Oxytocin 0
Chlorpromazine 0
Metoprolol 0
Succinylcholine 0
gentamycin 0
Adenosine 0
Etomidate 0
Atracurium 0
Phenytoin 1
Diazepam 1
Sulfamethoxazole + 
Trimethoprim 1
Folic acid 1
B Complex 1
Ascorbic acid (Vit. B) 1
Moxifloxacin 1
Streptomycin 1
Dopamine 1
Zofran® 1
Imipenem + Sodium cilastatin 1
Clarithromycin 1
Ampicillin 1
Filgrastim 1
Teicoplanin 1
Phytomenadione (vit. K) 1
Dexamethasone 1
Micafungin 1
continued…
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…continuation
DRUg no. OF PRESCRIPTIOnS DIVISIOn In gROUPS ACCORDIng TO THE FREQUEnCY OF PRESCRIPTIOnS
FREQUEnCY OF 
PRESCRIPTIOnS
Clindamycin 1
gROUP A < 5 PRESCRIPTIOnS
Hydroxyethylamide 1
Pancuronium 1
Atropine 1
ganciclovir 1
Amoxicillin + Sulbactam 2
Total Parenteral nutrition (TPn) 2
Cefazolin 2
Amiodarone 2
Polymyxin b 2
Calcium gluconate 2
Adrenaline 2
Dobutamine 3
Haloperidol 3
Metronidazole 3
Simple Ringer 3
Morphine 3
Amphotericin b liposomal 
complex 3
Acyclovir 3
Amikacin 3
Hypertonic glucose 50% 4
Potassium phosphate 4
Ceftriaxone 4
Sodium chloride 20% 4
Methylprednisolone 4
glucose solution 10% 5
gROUP B FROM 5 TO 10 PRESCRIPTIOnS
Piperacillin + Tazobactam 5
Ondansetron 5
Platelet concentrate 5
Tramadol 6
Human albumin 6
Fluconazole 6
Vancomycin 6
Regular purified mixed insulin 6
Vasopressin 6
Fresh Plasma 6
Packed red blood cells 7
Potassium chloride 10% 8
Magnesium sulfate 10% 8
Furosemide 8
Sodium bicarbonate 8.4% 11
gROUP C > 10 PRESCRIPTIOnS
glucose solution 50% 12
Meropenem 12
Midazolam 13
Ranitidine 14
Fentanyl® 14
glucose solution 5% 15
continued…
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…continuation
DRUg no. OF PRESCRIPTIOnS DIVISIOn In gROUPS ACCORDIng TO THE FREQUEnCY OF PRESCRIPTIOnS
FREQUEnCY OF 
PRESCRIPTIOnS
Hydrocortisone 17
gROUP C > 10 PRESCRIPTIOnS
noradrenaline 18
Metoclopramide 18
Bromopride 20
Omeprazole 23
Ringer lactate 24
Saline 
solution 0.9% 36
Dipyrone 44
Source: Created by the research authors.
(*) Omeprazole-Midazolam and Midazolam-Ranitidine are moderate drug interactions but were not found in the Micromedex® 
Healthcare Series.
Figure 3 – Theoretical potential drug interactions in the most relevant groups – Teaching Hospital, Rio de Janeiro, Rio de Janeiro, 
Brazil, 2014.   
Source: Figure drawn by the authors, resulting from the drug interactions calculated by the software Micromedex® Healthcare Se-
ries, 2011(8).
DISCUSSION
 The results of this study contribute to the evaluation of 
potential drug interactions in the ICU prescriptions. It is 
known that in intensive care the probability of a DI is high 
due to the environment’s high complexity, and prescriptions 
with many medications(2), which is called polypharmacy. 
These prescriptions are one of the main risk factors for the 
occurrence of drug interactions and adverse drug reactions, 
which are directly proportional to the increase in the number 
of drugs prescribed(1,9-10). Therefore, it is worth noting that the 
result of the mean number of drugs per patient of 9.3 is quite 
relevant and it presents a high probability of occurrence of 
drug interaction. Importantly, the risk of interactions raise to 
virtually 100% with eight or more medications prescribed(9).
The mean age of the patients was 58.2 years with a stan-
dard deviation of ± 17.07, which usually occurs in the inten-
sive care setting. Taking older age, physiological changes, and 
clinical condition’s severity into account, potential drug inter-
actions are important in this sector, even mild DIs, because 
they may have undesirable consequences, such as worsening 
of the clinical condition, increasing hospital length of stay(5).
Ninety-six types of medications were found in ICU pre-
scriptions. The knowledge about the drugs used and their 
potential drug interactions is extremely important, because 
they may occur more frequently, since a great variety of 
therapy increases the risk of DI considerably(2-5).
This knowledge should not be exclusive to a professional 
of the health team, but available to all professionals, favoring 
patient safety, and serving as clinical support for decision 
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making, which avoids more severe decompensations(3). The 
responsibility of the nursing staff within the multiprofes-
sional team is great. Regarding drug safety, nurses play an 
important role, as they are present during several stages of 
the drug process; thus, this professional can prevent drug 
interaction, for example, by identifying a potential interac-
tion in the prescription(11).
The most relevant classes of ICU prescriptions are usu-
ally associated with clinical and surgical characteristics of 
hospitalized patients(2), such as the need for electrolyte 
replacement, pain relief, the inherent risk of infection, and 
the prevention of peptic ulcers. Although this is described 
in the literature, it was not evidenced in the present study, as 
shown in Figure 1, where electrolytic replacements appear 
629 times, analgesics 358, antibiotics 265, and anti-peptic 
ulcers 252 times, as the most relevant drug classes.
Analgesics are characteristic of patients admitted to the 
ICU, since most of the time they undergo painful proce-
dures, and receive this medication class to provide relief and 
comfort(1). Another example is antibiotics, which are highly 
prescribed because of the high rates of infection in ICU, five 
to ten times higher than in other hospital units(12).
Figure 2 shows that the maximum number of drugs 
prescribed per patient is 23, and the minimum is 1 drug, 
configuring an amplitude of 22 drugs, which constitutes 
a particularity in the scenario investigated, both of clinical 
patients, who are in most cases critical patients, and surgical 
patients, who most of the time need less medications.
Chart 1 shows that groups B and C are the most relevant. 
Thus, it is important to call attention to the drugs that make 
up these groups, because their potential drug interactions 
may not always be serious, but are very likely to occur.
Following the analysis by the Micromedex® Healthcare 
Series software, based on the drugs mapped, potential 
drug interactions classified as serious were identified, 
such as: Tramadol-Fluconazole, Fluconazole-Fentanyl®, 
Fluconazole-Vasopressin, Midazolam-Fentanyl®, 
Ranitidine-Fentanyl®; and Tramadol-Metoclopramide. 
Therefore, the nurses’ knowledge about the drugs that will 
be administered is extremely important for the prevention of 
DI, because knowing potential drug interactions makes the 
professional able to identify them early, allowing for rapid 
intervention, since serious interactions are classified this way 
because they can lead to death.
The concomitant administration of Tramadol and selective 
serotonin reuptake inhibitor drugs, such as Metoclopramide 
and Fluconazole, increases the risk of seizures, because these 
agents are often individually epileptogenic, and may have 
additive effects when combined(13). Fluconazole-Fentanyl® 
interaction increases or prolongs the sedative effects of 
Fentanyl® because Fluconazole inhibits the cytochrome 
P450-3A4 enzyme complex (CYP4503A4), which is 
responsible for the biotransformation of Fentanyl®, increas-
ing serum levels of Fentanyl®, leading to an exacerbation of 
its sedation effect, increasing the risk of hypersedation(14).
The main consequence of concomitant administration 
of Midazolam-Fentanyl® is respiratory depression, but con-
comitant use of these drugs is commonly used based on 
pharmacological synergism, where they are used to provide 
comfort and relief of anxiety in patients on mechanical ven-
tilation(15). Ranitidine is an inhibitor of the enzyme system of 
opioids, which promotes an increase in the bioavailability and 
toxicity of opioids. Thus, the concurrent use of Ranitidine 
with Fentanyl® may lead to respiratory depression(9).
With all of these potential drug interactions raised in the 
present study, it is of paramount importance that the entire 
health team pays attention to drug prescriptions, so that early 
identification of TPDI takes place. Otherwise, the team 
should monitor the possible consequences, intervene and 
discuss suspension of the combination or dose adjustment(5).
 All health professionals should work together to form 
a multi-barrier and avoid unplanned DIs. This should take 
place as of the prescribing process (medical professional), 
through the scheduling of administration (nurses) and man-
agement (pharmacist and nursing staff ), up to medication 
administration (nursing team).
So that not only the drug process, but the entire patient 
care process is safe, communication among health care 
professionals should be effective. Studies recommend com-
munication as a daily competence in nursing care, both the 
communication among the multiprofessional team and com-
munication between the nurse and the individual receiving 
care, which conveys safety and comfort to the latter. Lack of 
communication or ineffective communication keeps the staff 
apart from patients and family members, and has a direct 
impact on the quality of care provided(16).
CONCLUSION
  The present study reiterates that polypharmacy, a daily 
situation in intensive care units, directly increases the risk 
of drug interaction. Attention to patients with a high num-
ber of drugs prescribed should be doubled. This makes the 
knowledge by all health professionals about each patient’s 
drug therapy of paramount importance for DI to be miti-
gated. The multiprofessional team should always be attentive 
to all phases of the drug process, from the prescription by 
the medical professional to the administration of the drug 
by the nursing team, acting as multi-barrier so that DI do 
not happen, or are early identified.
It should be noted that a previous mapping of prescrip-
tions allows the characterization of drug therapies, which 
contributes to prevent potential drug interactions, mini-
mizing the risk of harm to the patient’s clinical condition.
Nurses in particular should treat each prescription in a 
special way, considering the clinical and drug singularity of 
each patient, exercising their autonomy in the schedule of 
drug administration and also, if necessary, suggesting the sub-
stitution of medications. Therefore, as one of the main health 
assistants, nurses play a fundamental role in the prevention 
of drug interactions and their possible clinical consequences.
RESUMO
Objetivo: Analisar as potenciais interações medicamentosas intravenosas e seu grau de severidade associadas à administração desses 
medicamentos a partir das prescrições do Centro de Terapia Intensiva. Método: Estudo quantitativo, tipologia retrospectiva exploratória, 
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com análise estatística descritiva das prescrições medicamentosas do Centro de Terapia Intensiva de um Hospital Universitário no 
período de março-junho/2014. Resultados: A amostra foi composta de 319 prescrições e subamostras de 50 prescrições. Constatou-
se que a média de medicamentos por paciente foi de 9,3 registros, e evidenciou-se maior probabilidade para ocorrência de interação 
medicamentosa inerente à polifarmácia. O estudo identificou interações medicamentosas graves, como a administração concomitante de 
Tramadol com medicamentos inibidores seletivos da recaptação da serotonina, (exemplo: Metoclopramida e Fluconazol), aumentando o 
risco de convulsões devido às suas ações epileptogênicas, além do uso simultâneo de Ranitidina-Fentanil®, que pode ocasionar depressão 
respiratória. Conclusão: O mapeamento prévio das prescrições possibilita a caracterização da terapêutica medicamentosa, contribuindo 
para obstar as potenciais interações medicamentosas e suas consequências clínicas.
DESCRITORES
Interações de Medicamentos; Segurança do Paciente; Unidades de Terapia Intensiva; Enfermagem de Cuidados Críticos; 
Infusões  Intravenosas.
RESUMEn
Objetivo: Analizar las potenciales interacciones medicamentosas intravenosas y su grado de severidad asociadas con la administración 
de esos fármacos mediante las prescripciones del Centro de Cuidados Intensivos. Método: Estudio cuantitativo, tipología retrospectiva 
exploratoria, con análisis estadístico descriptivo de las prescripciones medicamentosas del Centro de Cuidados Intensivos de un Hospital 
Universitario en el período de marzo-junio/2014. Resultados: La muestra estuvo compuesta de 319 prescripciones y submuestras 
de 50 prescripciones. Se constató que el promedio de fármacos por paciente fue de 9,3 registros y se evidenció mayor probabilidad 
para ocurrencia de interacción medicamentosa inherente a la polifarmacia. El estudio identificó interacciones medicamentosas severas, 
como la administración concomitante de Tramadol con fármacos inhibidores selectivos de la recaptación de serotonina (por ejemplo: 
Metoclopramida y Fluconazol), aumentando el riesgo de convulsiones en virtud de sus acciones epileptogénicas, además del empleo 
simultáneo de Ranitidina-Fentanil®, lo que puede ocasionar depresión respiratoria. Conclusión: El mapeo previo de las prescripciones 
posibilita la caracterización de la terapéutica medicamentosa, contribuyendo a impedir las potenciales interacciones medicamentosas y 
sus consecuencias clínicas.
DESCRIPTORES
Interacciones de Drogas; Seguridad del Paciente; Unidades de Cuidados Intensivos; Enfermería de Cuidados Críticos; 
Infusiones  Intravenosas.
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